MOONFIRE-VENTURES
24.5.2023 10:01:33 CEST | Business Wire | Press release
Moonfire Ventures is today announcing it has raised $115 million to continue backing Europe’s best early-stage startups. Combining a human and tech approach, Moonfire uses proprietary machine learning models and software across the VC value chain to transform venture, solving founder challenges at scale, with greater knowledge and speed.
Through this Moonfire is embracing the new age of AI that is redefining how tech companies are built, driving further access, efficiency and product quality while revolutionising the startup opportunity for founders.
Moonfire: A tech firm transforming venture
Since its launch in 2020, by former Atomico co-founder Mattias Ljungman, Moonfire has been building the most advanced quantitative VC firm in Europe. A firm that is as much a VC-focused tech startup as it is a VC firm and its VCs are as much investors as they are product managers. The team isn’t using off-the-shelf tools, it’s built custom AI models and a large-scale tech stack from the ground up, allowing it to integrate tech across the full VC value chain, from founder discovery to exit.
It’s a symbiotic, proprietary approach that sees the AI help the investors make better decisions; while the investors and on-hand engineers can directly and continuously improve the AI in response to evolving trends and market shifts. All of which directly benefits founders by enabling its investors to build deeper founder relationships.
Moonfire’s technical power, when combined with the team’s operator experience, is a key draw for founders looking for a partner to help them solve their hardest technical challenges. Such as how to harness the power of AI and machine learning – an opportunity the Moonfire team is uniquely placed to help founders maximise, alongside traditional areas like hiring, go-to-market and fundraising. Such is the impact of its approach, Moonfire believes it represents the future of VC by enabling its team to be more impactful, more productive, and drive more value for its founders. A key step in the rise of the 10x VC.
Maths with words
Having defined this approach with Fund I, Moonfire is taking it to the next level with Fund II.
Moonfire now reviews up to 50,000 companies every week – more than 600 times the average of a traditional VC – in search of the very best founding teams in Europe using next-level technologies like AI, Web3, and AR/VR to transform four key sectors – health, work, finance and gaming. Moonfire describes this focus as “where sources of disruption intersect with sectors that are driving innovation” and believes this is key in the pursuit of a more accessible, sustainable and equitable society.
Such is the importance of this thesis, it forms the basis of Moonfire’s AI company evaluation and is the worldview upon which its algorithms model themselves. Using this mathematical representation of its written thesis, Moonfire’s AI is able to discover companies and founders that align with this unique worldview. It empowers investors to make better decisions, faster; it makes VC more inclusive: finding overlooked talent early, more frequently, and with greater accuracy.
Moonfire’s investment into UK Fintech LiveFlow is an example of its tech-first approach in action. Having sourced LiveFlow through its AI engine, Moonfire led the Pre-Seed round alongside Seedcamp and then used the Moonfire team’s technical expertise to build a recruitment funnel that empowered LiveFlow to hire a new, highly experienced CTO. LiveFlow went on to raise a $4 million Seed round, at more than double its initial pre-Seed valuation.
Moonfire Ventures’ Managing Partner Mattias Ljungman said:
“We are entering a new decade of AI that is transforming the possibilities of technology and redefining how tech companies are built through greater access, efficiency and product quality. We want to be there for the founders at the earliest stages powering their growth and being true partners from the very beginning. Europe has been a leader in AI and we find our best fit is to support the next generation of founders solving some of our greatest challenges within health, work, finance and gaming."
Building on success
Ljungman founded Moonfire using insight from 20+ years investing in tech leaders, from Klarna ($6.5bn) to Supercell ($10bn). Partner Mike Arpaia is a computer scientist focused on AI and quantitative finance. He was previously co-founder and CTO of security platform Kolide, and formerly tech lead at Facebook, Etsy, and Workday. Joining Ljungman and Arpaia is a team of entrepreneurs and technologists, 90% of whom have founded and scaled companies themselves.
To date, the Moonfire team has led 23 deals and co-invested in a further 27 with top-tier investors Sequoia, Accel, Index, General Catalyst and Accel since having joined its founders' journeys. Notable successes from Fund I include portfolio company Humaans recently raising a $15m Series A round, Lightdash completing a $7M round led by Accel, and GOALS closing a $20m Series A round with Seven Seven Six. In addition to its $90M Fund II, the firm has raised $25M to double down on its winners via its Opportunity Fund.
Moonfire Ventures partner and computer scientist Mike Arpaia said:
“The power of the AI and VC partnership has always been at the core of Moonfire and, with the launch of Fund II, we see it move to the next level. This new level combines human and machine like never before, hoping to turn an inefficient and inequitable industry on its head. With AI solving the mental-manual work, we can focus on the aspects humans are better at – meeting and forming relationships with founders.”
– ENDS –
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230524005108/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
